Osteoporosis prevention and treatment in elderly men—a cost-effective strategy

Osteoporosis prevention and treatment in elderly men—a cost-effective strategy

Play all audios:

Loading...

Access through your institution Buy or subscribe boxed-textSchousboe JT _ et al_. (2007) Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men. _JAMA_ 298: 629–637 BACKGROUND This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 12 print issues and online access $209.00 per year only $17.42 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support REFERENCES * Center JR _ et al_. (2007) Risk of subsequent fracture after low-trauma fracture in men and women. _JAMA_ 297: 387–394 Article  CAS  Google Scholar  * Center JR _ et al_. (1999) Mortality after all major types of osteoporotic fracture in men and women: an observational study. _Lancet_ 353: 878–882 Article  CAS  Google Scholar  * Kaufman JM _ et al_. (2005) Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. _Osteoporos Int_ 16: 510–516 Article  CAS  Google Scholar  * Lyles KW _ et al_. (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. _N Engl J Med_ 357: 1799–1809 Article  CAS  Google Scholar  * Nguyen ND _ et al_. (2007) Development of a nomogram for individualizing hip fracture risk in men and women. _Osteoporos Int_ 18: 1109–1117 Article  CAS  Google Scholar  Download references ACKNOWLEDGEMENTS The synopsis was written by Vicky Heath, Associate Editor, Nature Clinical Practice. AUTHOR INFORMATION Author notes * Bone and Mineral Research Program, Garvan Institute of Medical Research, 384 Victoria Street, Sydney, NSW 2010, Australia j.eisman@garvan.org.au AUTHORS AND AFFILIATIONS * JA Eisman is the Director of the Bone and Mineral Research Program, Garvan Institute of Medical Research, Professor of Medicine (Adjunct), University of New South Wales, and Senior Staff Endocrinologist at St Vincent's Hospital, Sydney, Australia., John A Eisman Authors * John A Eisman View author publications You can also search for this author inPubMed Google Scholar ETHICS DECLARATIONS COMPETING INTERESTS Dr Eisman has participated in multicenter international studies, received research funding and/or served as a consultant for Amgen (consultant, advisory board, study investigator), deCode Genetics (consultant), Eli Lilly (consultant, advisory board, study investigator), GE Lunar (consultant), Merck, Sharp and Dohme (consultant, advisory board), Novartis (consultant, advisory board, study investigator), NPS Pharmaceuticals (consultant), Organon (consultant, study investigator), Roche-GSK (consultant, advisory board, study investigator), Sanofi-Aventis (consultant, advisory board), Servier (consultant, advisory board), and Wyeth Australia (consultant). RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Eisman, J. Osteoporosis prevention and treatment in elderly men—a cost-effective strategy. _Nat Rev Endocrinol_ 4, 198–199 (2008). https://doi.org/10.1038/ncpendmet0753 Download citation * Received: 16 October 2007 * Accepted: 20 November 2007 * Published: 05 February 2008 * Issue Date: April 2008 * DOI: https://doi.org/10.1038/ncpendmet0753 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative

Access through your institution Buy or subscribe boxed-textSchousboe JT _ et al_. (2007) Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men. _JAMA_


298: 629–637 BACKGROUND This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 12 print


issues and online access $209.00 per year only $17.42 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to


local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support REFERENCES * Center


JR _ et al_. (2007) Risk of subsequent fracture after low-trauma fracture in men and women. _JAMA_ 297: 387–394 Article  CAS  Google Scholar  * Center JR _ et al_. (1999) Mortality after all


major types of osteoporotic fracture in men and women: an observational study. _Lancet_ 353: 878–882 Article  CAS  Google Scholar  * Kaufman JM _ et al_. (2005) Teriparatide effects on


vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. _Osteoporos Int_ 16: 510–516 Article  CAS  Google Scholar  * Lyles KW _ et


al_. (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. _N Engl J Med_ 357: 1799–1809 Article  CAS  Google Scholar  * Nguyen ND _ et al_. (2007) Development of a


nomogram for individualizing hip fracture risk in men and women. _Osteoporos Int_ 18: 1109–1117 Article  CAS  Google Scholar  Download references ACKNOWLEDGEMENTS The synopsis was written


by Vicky Heath, Associate Editor, Nature Clinical Practice. AUTHOR INFORMATION Author notes * Bone and Mineral Research Program, Garvan Institute of Medical Research, 384 Victoria Street,


Sydney, NSW 2010, Australia [email protected] AUTHORS AND AFFILIATIONS * JA Eisman is the Director of the Bone and Mineral Research Program, Garvan Institute of Medical Research,


Professor of Medicine (Adjunct), University of New South Wales, and Senior Staff Endocrinologist at St Vincent's Hospital, Sydney, Australia., John A Eisman Authors * John A Eisman View


author publications You can also search for this author inPubMed Google Scholar ETHICS DECLARATIONS COMPETING INTERESTS Dr Eisman has participated in multicenter international studies,


received research funding and/or served as a consultant for Amgen (consultant, advisory board, study investigator), deCode Genetics (consultant), Eli Lilly (consultant, advisory board, study


investigator), GE Lunar (consultant), Merck, Sharp and Dohme (consultant, advisory board), Novartis (consultant, advisory board, study investigator), NPS Pharmaceuticals (consultant),


Organon (consultant, study investigator), Roche-GSK (consultant, advisory board, study investigator), Sanofi-Aventis (consultant, advisory board), Servier (consultant, advisory board), and


Wyeth Australia (consultant). RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Eisman, J. Osteoporosis prevention and treatment in elderly men—a


cost-effective strategy. _Nat Rev Endocrinol_ 4, 198–199 (2008). https://doi.org/10.1038/ncpendmet0753 Download citation * Received: 16 October 2007 * Accepted: 20 November 2007 * Published:


05 February 2008 * Issue Date: April 2008 * DOI: https://doi.org/10.1038/ncpendmet0753 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get


shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative